

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 05:37:57 ON 02 OCT 2007  
FILE 'CAPLUS' ENTERED AT 05:37:57 ON 02 OCT 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.82	175.13

=> file reg

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.76	176.07

FILE 'REGISTRY' ENTERED AT 05:39:06 ON 02 OCT 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2007 HIGHEST RN 948988-82-7  
DICTIONARY FILE UPDATES: 1 OCT 2007 HIGHEST RN 948988-82-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10586765.str

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 C,H,O,Cl,Br,F,OH,Cy,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s 15 full

FULL SEARCH INITIATED 05:39:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 99448 TO ITERATE

100.0% PROCESSED 99448 ITERATIONS  
SEARCH TIME: 00.00.01

104 ANSWERS

L6 104 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

348.17

FILE 'CAPLUS' ENTERED AT 05:39:47 ON 02 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2007 VOL 147 ISS 15

FILE LAST UPDATED: 1 Oct 2007 (20071001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 16 full

L7 7 L6



=> d ibib abs hitstr tot.

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2006:301787 CAPLUS  
DOCUMENT NUMBER: 144:350698  
TITLE: Preparation of benzoxazine derivatives as modulators  
of chemokine receptors for treatment of inflammation  
and immunoregulatory diseases  
INVENTOR(S): Goble, Stephen D.; Mills, Sander G.; Yang, Lihu;  
Pasternak, Alexander; Bonnefous, Celine; Kamenecka,  
Theodore M.; Vernier, Jean-Michel; Hutchinson, John  
H.; Hu, Essa; Govek, Steven  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 94 pp., Cont.-in-part of Appl.  
No. PCT/US04/011281.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006069088	A1	20060330	US 2005-129512	20050513
WO 2004092124	A2	20041028	WO 2004-US11281	20040408
WO 2004092124	A3	20050414		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG

PRIORITY APPLN. INFO.: US 2003-463111P P 20030415  
WO 2004-US11281 A2 20040408  
OTHER SOURCE(S): MARPAT 144:350698  
GI



AB Title benzoxazine derivs. I [wherein X = C, N, O, or S; Y = O, S, SO, SO<sub>2</sub>, or (un)substituted NH; Z = C or N; R1 = H, (un)substituted alkoxy(alkyl), alkylthio(alkyl), heterocyclyloxy(alkyl), etc.; R2 = halo, (un)substituted alkyl, alkoxy(alkyl), alkylthio(alkyl), etc.; R3 = H, (un)substituted phenyl(alkyl), cycloalkyl(alkyl), heterocyclyl(alkyl), etc.; R4 = OH, CN, alkoxy, etc.; R5 and R6 = independently H, OH, halo, alkyl, alkoxy, etc.; when Z = C, R7 = H, OH, halo, (un)substituted alkyl, alkoxy, etc.; when Z = N, R7 is nothing or oxide; R8 = H, alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, halo, etc.; m and n = independently 0-2 wherein m + n = 0-3], or pharmaceutically acceptable salts or diastereomers thereof were prepared as modulators of CCR2 chemokine receptors. For example, II was prepared in a multi-step synthesis. The title compds. are useful as modulators of CCR-2 chemokine receptors for the prevention or treatment of inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis (no data).

IT 881493-17-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoxazine derivs. as modulators of chemokine receptors for treatment of inflammatory and immunoregulatory diseases)

RN 881493-17-0 CAPLUS

CN Benzoic acid, 3-[1-[(1R,3S)-3-(1-methylethyl)-3-[[6-(trifluoromethyl)-2H-pyrido[3,2-e]-1,3-oxazin-3(4H)-yl]carbonyl]cyclopentyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.





L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:696675 CAPLUS  
 DOCUMENT NUMBER: 143:193909  
 TITLE: Preparation of 2,6-disubstituted piperidines as modulators of chemokine receptors  
 INVENTOR(S): Yang, Lihu; Mills, Sander G.; Zhou, Changyou; Goble, Stephen D.; Pasternak, Alexander  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070133	A2	20050804	WO 2005-US770	20050114
WO 2005070133	A3	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005206791	A1	20050804	AU 2005-206791	20050114
CA 2553242	A1	20050804	CA 2005-2553242	20050114
EP 1732552	A2	20061220	EP 2005-711338	20050114
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1909906	A	20070207	CN 2005-80002715	20050114
JP 2007518799	T	20070712	JP 2006-551125	20050114
IN 2006DN03835	A	20070427	IN 2006-DN3835	20060704
US 2007179158	A1	20070802	US 2006-586765	20060720
PRIORITY APPLN. INFO.:			US 2004-537732P	P 20040120
			WO 2005-US770	W 20050114
OTHER SOURCE(S): CASREACT 143:193909; MARPAT 143:193909				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


- AB Title compds. I [R1 = H, OH, CN, etc.; R2 = H, (un)substituted alkyl or alkoxy; R3 = H, halo, OH, etc. when Y is C or R3 is oxygen or absent when Y is N; R4 = H, trifluoromethyl, trifluoromethoxy, etc.; R5 = (un)substituted alkyl, alkoxy, thioalkyl, etc.; R6 = H, alkyl, chloro, etc.; R7 = nothing when X is O, S, or SO<sub>2</sub> or R7 = H, alkylphenyl, alkylheterocycle, etc. when X is C or N; R8 = H, OH, alkyl, etc. when X is C or R8 = nothing when X is O, S, SO<sub>2</sub>, etc. or R7 and R8 together form a ring selected from (un)substituted 1H-indene, 2,3-dihydro-1H-indene, 2,3-dihydro-benzofuran, etc.; R9 and R10 independently = H, OH, alkyl, etc. or R7 and R9, or R8 and R10 together form (un)substituted Ph or heterocycle; R11, R13, R14 and R15 independently = H, OH, alkyl, etc.; R12 and R16 independently = OH, (un)substituted alkoxy, alkylhydroxy, etc. or R12 and R16 together form a bridge consisting of (un)substituted alkyl or alkyl-O-alkyl; R17 = H, (un)substituted Ph or alkyl or R2 and R17 together form a heterocycle; Q = (CH<sub>2</sub>)<sub>n</sub>; X = C, N, O, etc.; Y = N or C; Z = (CH<sub>2</sub>)<sub>0-1</sub>; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of chemokine receptors. Thus, e.g., II was prepared by Grignard reaction of N-carbethoxy-4-tropinone with Ph magnesium bromide followed by dehydration/hydrogenation/decarboxylation sequence and subsequent coupling with III (preparation given). The binding activity of I towards the CCR-2 receptor was evaluated and it was revealed that compds. of the invention are useful modulators of chemokine receptor activity (data given). I as modulator of chemokine receptors should prove useful in the treatment of rheumatoid arthritis. Pharmaceutical compns. comprising I are disclosed.
- IT 861853-56-7P 861855-43-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2,6-disubstituted piperidines as modulators of chemokine receptors)
- RN 861853-56-7 CAPLUS  
 CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)  
 (CA INDEX NAME)



- RN 861855-43-8 CAPLUS  
 CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1(1S)-1-(1-methylethyl)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:141023 CAPLUS

DOCUMENT NUMBER: 142:240424

TITLE: Preparation of (thiazolyl)cyclopentane amide modulators of chemokine receptor activity

INVENTOR(S): Butora, Gabor; Yang, Lihu; Goble, Stephen D.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014537	A2	20050217	WO 2004-US25467	20040806
WO 2005014537	A3	20050512		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004263509	A1	20050217	AU 2004-263509	20040806
CA 2534294	A1	20050217	CA 2004-2534294	20040806
EP 1654256	A2	20060510	EP 2004-780322	20040806
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1832943	A	20060913	CN 2004-80022756	20040806
JP 2007501795	T	20070201	JP 2006-522756	20040806
IN 2006DN00519	A	20070810	IN 2006-DN519	20060131
US 2006205783	A1	20060914	US 2006-567516	20060207
PRIORITY APPLN. INFO.:			US 2003-493902P	P 20030808
			WO 2004-US25467	W 20040806

OTHER SOURCE(S): CASREACT 142:240424; MARPAT 142:240424

GI



I



II

AB Title compds. I [wherein Z = independently C or N; R1 = (alkoxy)alkyl, alkylthioalkyl, hydroxy, etc.; R2-R4, R6 = independently H, OH, alkyl, halo, etc.; R5 = (carbonyl)alkyl, CF3, halo, etc.; R7, R9 = independently H, Ph, alkyl, etc.; R8 = H, Ph, alkyl, etc.; R10 = (un)substituted tetrahydropyranyl-4-ylamino, azacyclohept-1-yl, azacyclooct-1-yl; and pharmaceutically acceptable salts or solvates thereof and individual diastereomers thereof] are prep'd as chemokine receptor modulators (no data). For example, II was given in a multi-step synthesis starting from 2,6-dichloro-4-trifluoromethylpyridine. The invention is directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. as chemokine receptor modulators in the prevention or treatment of the diseases in which chemokine receptors are involved, such as inflammatory and immunoregulatory disorders, and rheumatoid arthritis (no data).


IT 844639-97-0P 844639-99-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-pyridinylmethyl (thiazolyl)cyclopentane amide modulators of chemokine receptor activity)

RN 844639-97-0 CAPLUS


CN Carbamic acid, [4-[3-(hexahydro-1H-azepin-1-yl)-1-[[[5-(trifluoromethyl)-3-pyridinyl]methyl]amino]carbonyl]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 844639-99-2 CAPLUS

CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-3-(hexahydro-1H-azepin-1-yl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)





L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1124588 CAPLUS  
 DOCUMENT NUMBER: 142:69197  
 TITLE: CCR-2 antagonists for treatment of neuropathic pain  
 INVENTOR(S): Abbadie, Catherine; Lindia, Jill Ann; Wang, Hao  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 304 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110376	A2	20041223	WO 2004-US17499	20040602
WO 2004110376	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2006205761 A1 20060914 US 2005-559701 20051206  
 PRIORITY APPLN. INFO.: US 2003-476391P P 20030606  
 US 2003-531637P P 20031222  
 WO 2004-US17499 W 20040602

OTHER SOURCE(S): MARPAT 142:69197

AB The invention is directed to methods of treating neuropathic pain and other neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical composition containing CCR-2 antagonists.

IT 766513-14-8P 766513-16-0P 766513-18-2P  
 766513-20-6P 766513-22-8P 766513-24-0P  
 767332-04-7P 767332-05-8P 767332-06-9P  
 767332-07-0P 767332-08-1P 767332-09-2P  
 787638-91-9P 787638-92-0P 787638-93-1P  
 787638-94-2P 787638-95-3P 787638-96-4P  
 787638-97-5P 787638-98-6P 787639-19-4P  
 787639-25-2P 787639-26-3P 787639-27-4P  
 787639-28-5P 787639-87-6P 787639-88-7P  
 787639-89-8P 787639-90-1P 787639-91-2P  
 787639-92-3P 787639-93-4P 787639-94-5P  
 787639-95-6P 787639-96-7P 787639-97-8P


787639-98-9P 791067-33-9P 791067-36-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CCR2 antagonists for treatment of neuropathic pain)


RN 766513-14-8 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidiny)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 766513-16-0 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(4-phenyl-1-piperidiny)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 766513-18-2 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidiny)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 766513-20-6 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidiny)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 766513-22-8 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-24-0 CAPLUS


CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 767332-04-7 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 767332-05-8 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 767332-06-9 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 767332-07-0 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 767332-08-1 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 767332-09-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787638-91-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-92-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-93-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-94-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(4-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-95-3 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(3-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 787638-96-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-3-(3-hydroxy-1-piperidiny)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-97-5 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-3-(4-hydroxy-1-piperidiny)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-98-6 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S)-3-(1R,4S)-2-azabicyclo[2.2.1]hept-2-yl-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-19-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-25-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(4-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-26-3 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(3-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787639-27-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(2-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787639-28-5 CAPLUS

CN 3-Pyrrolidineacetic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-87-6 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-], (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-88-7 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-89-8 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-90-1 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-91-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-92-3 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(3H-pyrazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-93-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(5-methyl-2H-tetrazol-2-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-94-5 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(4-thiazolyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 787639-95-6 CAPLUS

CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 787639-96-7 CAPLUS

CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-97-8 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S)-3-[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-98-9 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791067-33-9 CAPLUS


CN 1,6-Naphthyridine, 6-[[[(1S)-3-(3,5-dimethyl-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791067-36-2 CAPLUS  
 CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[ (1S)-1-(1-methylethyl)-3-  
 [(4R,7S)-octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-  
 yl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:927165 CAPLUS  
 DOCUMENT NUMBER: 141:410822  
 TITLE: Preparation of heterocyclic cyclopentyl  
 tetrahydroisoquinoline and tetrahydropyridopyridine  
 modulators of chemokine receptor activity  
 INVENTOR(S): Butora, Gabor; Goble, Stephen D.; Pasternak,  
 Alexander; Yang, Lihu; Zhou, Changyou; Moyes,  
 Christopher R.  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited  
 SOURCE: PCT Int. Appl., 187 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

20040414

20050324

W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
	RW:
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,	
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,	
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,	
TD, TG	

20040414

20040414

20040414

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

20040414



20040414

P 20030417

W 20040414

MARPAT 141:410822

GI



AB Title compds. I [X = C, N, O, S, SO<sub>2</sub>; Y = N, C; R<sub>1</sub> = H, alkyl, etc.; R<sub>2</sub> = H, OH, halo, alkyl, amino, etc.; R<sub>3</sub> = O or absent when Y = N and when Y = C, H, OH, halo, etc.; R<sub>4</sub> = H, alkyl, CF<sub>3</sub>, etc.; R<sub>5</sub> = alkyl, alkoxy, etc.; R<sub>6</sub> = H, alkyl, CF<sub>3</sub>, etc.; R<sub>7</sub> = H, (alkyl)phenyl, (alkyl)heterocycle, etc.; R<sub>8</sub> = H, nothing when X = O, S, SO<sub>2</sub>, etc.; R<sub>9</sub>-10 = H, OH, alkyl, etc.; n = 0-2] are prepared. For instance, II is prepared in several steps from 7-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline (preparation given), Me 3-oxocyclopentanecarboxylate and 4-carboethoxypiperidine. I are modulators of the chemokine receptor CCR-2.


IT 787638-99-7P 787639-00-3P  
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity)

RN 787638-99-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(1S,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 787639-00-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

IT 787639-04-7P 787639-05-8P 787639-06-9P  
 787639-07-0P 787639-08-1P 787639-09-2P  
 787639-10-5P 787639-11-6P 787639-12-7P  
 787639-13-8P 787639-14-9P 787639-15-0P  
 787639-22-9P 787639-23-0P 787639-82-1P  
 787639-83-2P 787639-85-4P 787639-86-5P  
 787640-61-3P 787640-62-4P 791067-35-1P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity)

RN 787639-04-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(1S,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 787639-05-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 787639-06-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[(1S,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-07-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-08-1 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3S)-1-(1-methylethyl)-3-[(3R)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● x HCl

RN 787639-09-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3S)-1-(1-methylethyl)-3-[(3S)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-10-5 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3R)-1-(1-methylethyl)-3-[(3S)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-11-6 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3R)-1-(1-methylethyl)-3-[(3R)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-12-7 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S,3R)-3-[(3S,5R)-3,5-dimethyl-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-13-8 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S,3S)-3-[(3S,5R)-3,5-dimethyl-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-14-9 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3S)-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-15-0 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3R)-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 787639-22-9 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3S)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 787639-23-0 CAPLUS  
 CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3R)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 787639-82-1 CAPLUS  
 CN 1,6-Naphthyridine, 6-[[[(1S,3S)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-83-2 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S,3R)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-85-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3R)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-86-5 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3S)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787640-61-3 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S,3R)-3-[(3R,5R)-3,5-dimethyl-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-,  
hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 787640-62-4 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S,3S)-3-[(3R,5R)-3,5-dimethyl-1-piperidiny]l]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 791067-35-1 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S)-3-(3,5-dimethyl-1-piperidiny]l)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● x HCl


IT 787638-91-9P 787638-93-1P 787638-95-3P  
 787639-19-4P 787639-84-3P 791067-33-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity)  
 RN 787638-91-9 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-93-1 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-95-3 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(3-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-19-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-84-3 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791067-33-9 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S)-3-(3,5-dimethyl-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 787638-88-4P 787638-89-5P 787638-90-8P  
 787638-92-0P 787638-94-2P 787638-96-4P  
 787638-97-5P 787638-98-6P 787639-01-4P  
 787639-02-5P 787639-03-6P 787639-24-1P  
 787639-25-2P 787639-26-3P 787639-27-4P  
 787639-28-5P 787639-87-6P 787639-88-7P  
 787639-89-8P 787639-90-1P 787639-91-2P  
 787639-92-3P 787639-93-4P 787639-94-5P  
 787639-95-6P 787639-96-7P 787639-97-8P  
 787639-98-9P 787639-99-0P 787640-00-0P  
 787640-01-1P 787640-02-2P 787640-54-4P  
 791067-36-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity)


RN 787638-88-4 CAPLUS

CN 1,6-Naphthyridine, 6-[[3-(4-benzoyl-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 787638-89-5 CAPLUS


CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(1-oxo-2,8-diazaspiro[4.5]dec-8-yl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 787638-90-8 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-92-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(3S)-3-[[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-94-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(4-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787638-96-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-3-(3-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 787638-97-5 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 787638-98-6 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S)-3-(1R,4S)-2-azabicyclo[2.2.1]hept-2-yl-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-01-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(1S,3S)-3-[[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 787639-02-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 787639-03-6 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S,3R)-3-[4-(hydroxymethyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






●x HCl

RN 787639-24-1 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(1-pyrrolidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-25-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(4-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-26-3 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(3-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787639-27-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(2-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787639-28-5 CAPLUS

CN 3-Pyrrrolidineacetic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-87-6 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-88-7 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-89-8 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-90-1 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[ (1S)-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-91-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[ (1S)-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-92-3 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(3H-pyrazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-93-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(5-methyl-2H-tetrazol-2-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-94-5 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[4-(4-thiazolyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787639-95-6 CAPLUS

CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-96-7 CAPLUS

CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 787639-97-8 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S)-3-[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 787639-98-9 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787639-99-0 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-hydroxyethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787640-00-0 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-hydroxyethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787640-01-1 CAPLUS

CN 1,6-Naphthyridine, 6-[[[(1S,3R)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(methoxymethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787640-02-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1R,3R)-3-(4-phenyl-1-piperidinyl)-1-(trifluoromethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 787640-54-4 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-(1-pyrrolidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 791067-36-2 CAPLUS



CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[[(1S)-1-(1-methylethyl)-3-[(4R,7S)-octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-yl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:802715 CAPLUS  
 DOCUMENT NUMBER: 141:314157  
 TITLE: Preparation of amino cyclobutylamide modulators of chemokine receptor activity  
 INVENTOR(S): Jiao, Richard; Yang, Lihu  
 PATENT ASSIGNEE(S): Merck & Co. Inc., USA  
 SOURCE: PCT Int. Appl., 108 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082682	A1	20040930	WO 2004-US7792	20040315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222336	A1	20040930	AU 2004-222336	20040315
CA 2519220	A1	20040930	CA 2004-2519220	20040315
EP 1617841	A1	20060125	EP 2004-720791	20040315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1787818	A	20060614	CN 2004-80013143	20040315
JP 2006520783	T	20060914	JP 2006-507176	20040315
IN 2005DN03929	A	20070824	IN 2005-DN3929	20050902
US 2006211722	A1	20060921	US 2005-549739	20050919
PRIORITY APPLN. INFO.:			US 2003-456047P	P 20030318
			WO 2004-US7792	A 20040315
OTHER SOURCE(S):		MARPAT 141:314157		
GI				



AB Title compds. represented by the formula I [wherein Z = independently C or N; R1 = H, heterocycle, Ph, cyano, etc.; R2-R4, R6 = independently H, (fluoro)alkyl, hydroxy, chloro, etc.; R5 = (fluoro)alkyl, (un)substituted pyridyl, bromo, etc.; R7-R9 = independently H, :O, Ph, (un)substituted alkyl; or R2R9 = heterocycle; A = (un)substituted amino or N-containing cyclic ring; and pharmaceutically acceptable salts and individual diastereomers thereof] were prepared as chemokine receptor modulators (no data). For example, II was given in a multi-step synthesis starting from the reaction of 3,5-bis(trifluoromethyl)benzylamine with 3-oxo-cyclobutanecarboxylic acid. Thus, I and their pharmaceutical compns. are useful as modulators of the chemokine receptor CCR-2 for the treatment of inflammatory and immunoregulatory disorders, and rheumatoid arthritis (no data).

IT 766513-12-6P 766513-14-8P 766513-16-0P  
 766513-18-2P 766513-20-6P 766513-22-8P  
 766513-24-0P 766513-57-9P 767332-04-7P  
 767332-05-8P 767332-06-9P 767332-07-0P  
 767332-08-1P 767332-09-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (piperidinyl)cyclobutylamide modulators of chemokine receptor activity)

RN 766513-12-6 CAPLUS


CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, cis-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 766513-14-8 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 766513-16-0 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 766513-18-2 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 766513-20-6 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidiny)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 766513-22-8 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidiny)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-24-0 CAPLUS


CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidiny)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 766513-57-9 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, trans-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 767332-04-7 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 767332-05-8 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 767332-06-9 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 767332-07-0 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 767332-08-1 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[5-(trifluoromethyl)-3-pyridinyl]methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 767332-09-2 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:142517 CAPLUS  
 DOCUMENT NUMBER: 136:200102  
 TITLE: Preparation of N-cyclopentylpiperidines as modulators of chemokine receptor activity  
 INVENTOR(S): Yang, Lihu; Butora, Gabor; Parsons, William H.; Pasternak, Alexander  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 274 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013824	A1	20020221	WO 2001-US25335	20010813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419194	A1	20020221	CA 2001-2419194	20010813
AU 200183345	A	20020225	AU 2001-83345	20010813
EP 1318811	A1	20030618	EP 2001-962140	20010813
EP 1318811	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004506013	T	20040226	JP 2002-518967	20010813
AT 337782	T	20060915	AT 2001-962140	20010813
ES 2271063	T3	20070416	ES 2001-1962140	20010813
US 2002049222	A1	20020425	US 2001-931454	20010816
US 6545023	B2	20030408		
PRIORITY APPLN. INFO.:				
			US 2000-225923P	P 20000817
			WO 2001-US25335	W 20010813

OTHER SOURCE(S): MARPAT 136:200102  
 GI



AB The title compds. I (R1 = H, (un)substituted C0-6alkyl-Y-C1-6alkyl and C0-6alkyl-Y-C0-6alkyl-C3-7cycloalkyl-C0-6alkyl wherein Y = bond, O, S, SO, SO2 and alkylamine; R2 = (un)substituted C0-6alkyl-Ph and C0-6alkyl-heterocycle; R3 = (un)substituted C0-6alkyl-phenyl; R4 = H, OH, alkyl, alkylhydroxy, CN, etc. or R3 and R4 may be joined to form a ring selected from 1H-indene, 2,3-dihydro-1H-indene, 1,3-dihydrobenzofuran, 1,3-dihydroisobenzofuran, 2,3-dihydrobenzothiofuran, and 1,3-dihydroisobenzothiofuran or R3 and R5 or R4 and R6 may be joined to form a (un)substituted Ph ring; R5 and R6 may also be independently selected from H, OH, alkyl, halo, etc.; X = NR7, O, CONR7, CH2O, NR7CO, CO2, OCO, CH2(NR7)CO, N(COR7) and CH2N(COR7) where R7 = H, (un)substituted -alkyl, -benzyl, -Ph, and -C1-6alkyl-C3-6cycloalkyl) are prepared and disclosed as modulators of chemokine receptor activity. Thus, II was prepared by ozonolysis of Et 3-methylenecyclopentane carboxylate, substitution with trans-3-methyl-4-(1,1-spiroindeny)l)piperidine (preparation given), hydrolysis of intermediate Et spiropiperidinylmethylcyclopentane carboxylate and subsequent amidation by 3-trifluoromethyl-5-fluorobenzylamine. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2 (no data). As chemokine receptor modulators, these compds. may be useful as anti-inflammatory and antirheumatic agents.

IT 400763-83-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400763-83-9 CAPLUS

CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his